Interaction Effects of Temperature and Ozone (TROPICOZ)

February 9, 2015 updated by: David Diaz-Sanchez, Environmental Protection Agency (EPA)

Purpose: The purpose of this protocol is to understand how individuals respond to the air pollutant ozone at elevated temperatures. Ultimately, this will help us understand what the risks from poor air quality are during a heat wave.

Participants: We will recruit up to 30 healthy adults, 18-55 years old, to participate in this study.

Procedures (methods): Subjects will be exposed to clean air and to 0.3 ppm of ozone for 2 hours with intermittent exercise in a controlled environment chamber. For each exposure the temperature in the chamber will be between 31-34oC (88-93 oF). Because the aim of the study is to mimic high exposure during a heat wave, we will perform exposures only on days when mean ambient temperatures was less than 24 oC in Chapel Hill on the previous day.

Primary endpoints will include spirometry and Heart Rate Variability monitoring. Secondary endpoints will include analysis of blood clotting/coagulation factors, and analysis of soluble factors present in plasma.

Study Overview

Detailed Description

Over the past decades, air quality in the U.S. has improved significantly. Even so, millions of people in the U.S. still live in counties that do not meet air quality standards for one or more pollutants. Global climate change is widely accepted to be occurring and is thought to have a range of major and potentially adverse effects on the ecosystem. Additionally, changes in the climate can lead to higher concentrations of harmful air pollutants, and the presence of some air pollutants in the atmosphere can also accelerate climate change. Health effects are impacted by complex interactions between climate change and air quality. Research is needed to identify the public health consequences of these interactions. One aspect that has been understudied is how physiological responses to elevated temperature are impacted by the additional stressor of air pollution.

Several epidemiological studies have shown a strong link between exposure to air pollution and adverse cardiopulmonary effects, such as respiratory tract infections, exacerbation of asthma, chronic bronchitis, ischemic heart disease, and stroke [1-3]. Ozone is a major component of photochemical smog. Controlled human exposure studies have been critical in demonstrating that it can cause decrements in lung function [4-10] and lung inflammation.[11-13] The inflammation includes increased neutrophils and soluble pro-inflammatory mediators in the lower airways [14, 15].

The majority of these studies involved controlled exposures to relatively high (0.1 - 0.4ppm) concentrations for short periods of time (typically 2 hours). These short-term exposure studies are useful because a) they provide the strongest and most quantifiable exposure-response data and b) they allow the investigation of biological changes that in themselves are transient and inconsequential but can be extrapolated to predict health outcomes in susceptible populations or in long-term exposures. For example, healthy individuals exposed to 0.4ppm ozone exposure for 2hr [16] showed a13.5 % decrement in FEV1, often accompanied by only mild symptoms such as tracheobronchial irritation and cough. However, by 3hours after exposure, these symptoms had largely disappeared and only a 2.7% FEV1 decrement was detectable. By 24hrs, even at higher ozone concentrations the recovery phase has normally completed. The primary public health concern is in individuals with respiratory disease. If these same changes occurred in a person with reduced reserve, the ozone-induced changes would be superimposed on preexisting pulmonary impairment and may have significant health effects.

Despite almost 30 years of research into the effects of ozone, there are very few studies of the interaction between ozone and temperature. Although ozone is normally elevated when the weather is dry and hot, most controlled chamber studies are performed at moderate temperatures (70-75 oF). Those studies that addressed higher temperatures were generally performed in the run-up to the Los Angeles Olympics in 1984 and centered on impairment of exercise performance. For example, Gibbons and Adams studied ten aerobically trained young adult females exercised continuously at 66% of maximum O2 uptake for 1 h while exposed orally to filtered air and 0.15 and 0.30 ppm ozone in both moderate (24 degrees oC) and hot (35 degrees oC) ambient conditions and showed that subjects were more likely to cease exercising prematurely at hot temperatures.[17] Gong studied elite cyclists and showed similar results.[18] Folinsbee et al., studied the effects of a 2-h exposure to high level ozone (0.5 ppm) in 14 nonsmoking males under four environmental conditions (64.4, 80.0, 85.2, and 92.0 oF) and found that the greatest decrease in FVC occurred when ozone exposures were at the highest temperature.[19]

Those cited studies have focused on respiratory outcomes. Yet it is becoming clear that ozone may have systemic and cardiac effects. Ozone reacts rapidly with respiratory tissues and is not absorbed or transported to extrapulmonary sites. However, recent studies have also shown associations between long-term ozone exposure and cardiovascular morbidity [20, 21]. In addition, short-term exposures to ozone may cause minor transient changes in high frequency heart rate variability (HRV) in healthy adults [22]. Experimental studies have shown that heat stress can have a similar modest effect on this component of HRV. [23] The effect of the combination has not been studied to date. Epidemiology studies assessing the ozone-temperature-cardiac relationship have generally been uninformative since high ozone days normally occur during hot weather. Traditional methods are not suitable to discriminate between the effects of ozone and temperature, let alone their interaction. Those that have studied the relationship have shown a negative association between temperature and ozone-mortality due to increased use in air conditioning. [24] A very recent study, however, using novel approaches examined whether ozone modified the associations between temperature and cardiovascular mortality in 95 large communities in the USA, 1987-2000, in summer. They found that a 10oC increase in temperature on the same day was associated with an increase in mortality by 1.17% and 8.31% for the lowest and highest level of ozone concentrations in all communities, respectively.[25]

The purpose of this study is to perform the first controlled chamber study in order to understand the cardiovascular changes resulting from the interaction between heat and ozone. The information obtained from this study will enable the EPA to evaluate better the risks from air pollutants during a heat wave and provide advice on activities to mitigate the effects.

Study Type

Interventional

Enrollment (Actual)

16

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • North Carolina
      • Chapel Hill, North Carolina, United States, 27514
        • U.S. EPA Human Studies Facility

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 55 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 1. Pass a physical exam performed by study physicians during the screening visit under a separate protocol.

    2. Normal lung function:

    1. FVC > 75 % of that predicted for gender, ethnicity, age and height.
    2. FEV1 > 75 % of that predicted for gender, ethnicity, age and height.
    3. FEV1/FVC ratio > 75 % of predicted values. 3. Oxygen saturation of > 96 %. 4. Ability to tolerate intervals of moderate exercise.

      Exclusion Criteria:

  • 1. A history of chronic illnesses such as diabetes, rheumatological diseases, immunodeficiency state, known clinically significant cardiac disease (including myocardial infarction, congestive heart failure and angina), chronic respiratory diseases such as chronic obstructive pulmonary disease, asthma and lung cancer.

    2. If the subject is pregnant, attempting to become pregnant or breastfeeding. 3. Subjects currently taking medications which may impact the results of the ozone challenge or interfere with any other medications potentially used in the study (to include systemic steroids and beta blockers). Subjects must refrain from all over the counter anti-inflammatory agents, and anti-oxidants for a period of one week prior to exposure. Medications not specifically mentioned here may be reviewed by the investigators prior to a subject's inclusion in the study.

    4. Smoking history within 2 years of the study. 5. Untreated hypertension (≥ 150 systolic, ≥ 90 diastolic). 6. Skin diseases or sensitivity precluding the use of ECG electrodes. 7. Symptom score greater than 21 (out of a possible 40-see accompanying score sheet) for total symptom score. Only one score may be equal to 3.

    8. Dementia. 9. Unspecified illness or condition which in the judgment of the investigator might increase the risk associated with inhalation challenge or exercise.

    10. Subjects who do not understand or speak English. 11. Subjects who are unable to perform moderate exercise.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Ozone
Exposure to ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
Each subject will be exposed up to 0.3ppm ozone for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
Other Names:
  • O3
Sham Comparator: Clean Air
Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
Each subject will be exposed to clean air for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Forced expired volume in the first second (FEV1)
Time Frame: Pre exposure to 24hours post exposure
Forced expired volume in the first second (FEV1) is determined by spirometry performed on a dry seal spirometer interfaced to a computer.
Pre exposure to 24hours post exposure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Index of clotting/coagulation factor
Time Frame: Pre exposure to 24hours post exposure
Index of clotting/coagulation factors are the mean % changes in a basket of clotting/coagulation factors (d-dimer, PA-1, tPA, vWillebrand factor and plasminogen) in the blood following exposure to ozone vs. clean air.
Pre exposure to 24hours post exposure
Index of inflammatory markers
Time Frame: Pre exposure to 24hours post exposure
Index of inflammatory markers is the mean % changes in a basket of factors related to systemic inflammation (IL-6, IL-8, TNF-a, IL-b, CRP) in the blood following exposure to ozone vs. clean air.
Pre exposure to 24hours post exposure
Forced Vital Capacity
Time Frame: Pre exposure to 24hours post exposure
Forced Vital Capacity(FVC) is determined by spirometry performed on a dry seal spirometer interfaced to a computer.
Pre exposure to 24hours post exposure
Changes in heart rate variability
Time Frame: Pre exposure to 24hours post exposure
10 minute electrocardiogram recording (measured by Holter ECG) in which the subject has been resting for 20 minutes prior. Collected on a Mortara H12+ 12-Lead ECG Recorder (Mortara Instrument, Inc., Milwaukee, WI). The digitally recorded ECGs are sampled at 180 Hz.
Pre exposure to 24hours post exposure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: David Diaz-Sanchez, PhD, U.S. Environmental Protection Agency

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2011

Primary Completion (Actual)

March 1, 2014

Study Completion (Actual)

January 1, 2015

Study Registration Dates

First Submitted

October 22, 2013

First Submitted That Met QC Criteria

November 5, 2013

First Posted (Estimate)

November 11, 2013

Study Record Updates

Last Update Posted (Estimate)

February 10, 2015

Last Update Submitted That Met QC Criteria

February 9, 2015

Last Verified

February 1, 2015

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Exposure to Environmental Pollution, Non-occupational

Clinical Trials on Clean Air

Subscribe